Palisade Bio advances PALI-2108 toward Phase 2 trials in ulcerative colitis, Crohn's disease
Company reports Q2 2026 results and says it finished the regulatory and operational groundwork needed to start the Phase 2 ASCENTRA-UC trial in the second half of 2026.
SEC filing